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Contrast Echocardiography: 
Past, Present, and...Future?
The history of contrast echocardiography dates 
back to 1968, when Gramiak and Shah first 
noted the echocardiographic appearance of 
bubbles in green dye injections. Commercial 
contrast agents became available in Europe in 
1991 (Echovist, Berlex, Lachine, Quebec City, 
Canada) and in the U.S. in 1994 (Albunex, 
Mallinckrodt, St. Louis, Missouri), fol-
lowed by second generation contrast agents 
(Optison [GE, Waukesha, Wisconsin], 1997, 
and Definity [BMS, Billerica, Massachusetts], 
2001). Early adopting clinicians celebrated the 
use of contrast echocardiography in enhancing 
left ventricular borders in suboptimal studies, 
whereas scientists investigated their poten-
tial to quantify myocardial blood flow. An 
imaging technique that could simultaneously 
detect wall motion and measure perfusion 
was indeed the holy grail of coronary artery 
disease diagnostic testing. With growing use 
of these agents in academic and community 
echocardiography labs and a 2000 American 
Society of Echocardiography guideline touting 
that “the use of contrast enables acquisition of 
ultrasound images of improved quality. The 
technique is especially useful in…approximate-
ly 10% to 20% of routine echocardiographic 
examinations” (1), the future seemed close at 
hand indeed.
Unfortunately, echocardiography con-
trast agents have met several challenges. In 
November 2005, General Electric (GE) volun-
tarily recalled its agent, Optison, after a Food 
and Drug Administration (FDA) inspection 
raised concerns about manufacturing practices. 
In a consumer letter dated September 6, 2007, 
GE expressed “great pleasure” in announc-
ing its return to the market in “September/
October” (2), although the drug has yet to 
make its reappearance. In the meantime, the 
FDA has been investigating deaths associated 
with the use of Definity and issued a Black Box 
warning on October 12, 2007 (3). This label-
ing change states that “serious cardiopulmonary 
reactions, including fatalities have occurred 
during or within 30 min following Definity 
administration.” The warning goes on to rec-
ommend monitoring of vital signs, electrocar-
diography, and in some patients phosphorus 
dioxide saturation, during and for 30 min after 
administration (4). A similar Black Box warn-
ing is required by the FDA when Optison 
returns to the market. 
Although there is no doubt that the use 
of contrast enables acquisition of ultrasound 
images of improved quality, these setbacks in 
contrast agent safety are not the only prob-
lem. Over the years, adoption has been slower 
than expected, whether owing to initial low 
reimbursement or the “hassle factor” of an 
intravenous medication, and no agent has yet 
been approved for myocardial perfusion. No 
doubt, the recommendation for 30 min of 
monitoring could be difficult for busy echo labs 
to comply with, especially given recent cuts in 
reimbursement. However, adding it all up….is 
this simply a temporary setback for a clinically 
proven and widely valued technique, or is this 
the straw that will break the camel’s back of 
contrast echocardiography? 
What is the future for bubbles? We do real-
ize that there will be a significant delay by the 
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monitor vital signs, electrocardiography, and pO2 saturation for 30 min following administration. The warn-
ing was a result of an investigation of serious cardiopulmonary reactions, including fatalities, associated with 
ultrasound contrast administration.
V O L .  1 ,  N O .  1 ,  2 0 0 8
I S S N  1 9 3 6 - 8 7 8 X / 0 8 / $ 3 4 . 0 0
D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 0 7 . 1 0 . 0 0 5
time this issue of JACC: Cardiovascular 
Imaging reaches you. We have there-
fore invited expert comments on this 
recommendation. What do they have 
to say? Would you share your opinion 
with us? We encourage you to visit 
iJACC-iNEWS in Cardiosource and 
tell us what you feel. The opinions 
presented below are entirely of the 
authors and do not reflect or express 
the position of the American College 
of Cardiology, JACC: Cardiovascular 
Imaging, or the editors.
Pamela S. Douglas, MD, MACC 
Duke University
Will Contrast Survive?
Arthur E. Weyman, MD, FACC
Massachusetts General Hospital
I N  A  R E C E N T  R E L E A S E ,  the 
FDA reported 11 deaths after the 
administration of ultrasound micro-
bubble contrast agent Definity (3). 
Four of the 11 deaths occurred within 
30 min of injection: 1 patient died dur-
ing a stress test, 2 patients had severe 
congestive heart failure, and the fourth 
was undergoing mechanical ventila-
tion for respiratory failure. Although 
all complications are important, even 
this small number of cardiac deaths 
is particularly troubling. The mecha-
nism by which the microbubbles might 
have caused these deaths is unclear. 
Microbubbles can potentially affect the 
heart by mechanical obstruction of the 
coronary vessels or cause direct cell 
damage when destroyed in high-inten-
sity sound fields. Mechanical obstruc-
tion can occur when bubbles larger 
than capillary diameter are injected 
into the coronary circulation. In the 
case of Definity, however, the bubbles 
are generally smaller than the capil-
laries and should flow freely through 
the coronary circulation. Although a 
limited number of larger bubbles can 
be present in the overall distribution 
or injectate, they should be filtered out 
by the lungs. It is also possible that the 
contrast-containing microbubbles can 
dilute out the available red cells in areas 
of critically reduced perfusion, but the 
volume injected is small and further 
diluted by the flowing blood as it passes 
through the right heart, lungs, and left 
ventricle. The direct biological effects 
of contrast agents seem to be due to the 
destruction (inertial cavitation) of the 
microbubbles in high-intensity sound 
fields. Bubble destruction produces 
high-velocity fluid microjets that can 
penetrate adjacent membranes, lead-
ing to pore formation (sonoporation), 
secondary shock waves, transient high 
temperatures, and sheer stress. All of 
these effects are local, affecting only 
the area immediately surrounding the 
bubble. Although the specific combi-
nations of contrast dose, ultrasound 
pressure, delivery mode, and duration 
of ultrasound exposure that produce 
bioeffects have been extensively studied 
in rodent models and rabbits, there are 
limited data in large animals or humans. 
Recently, Miller et al. (5) reported 
increased vascular permeability and cell 
death in open-chest canine experiments, 
but only after long exposure (10 min) to 
high mechanical index (relatively high 
intensity) scanning with a fixed plane. 
In a clinical study, Vancraeynest et al. 
(6) observed that combined exposure to 
an ultrasound contrast agent (PESDA) 
and prolonged high mechanical index 
ultrasound imaging resulted in a slight 
increase in cardiac biomarkers (tropo-
nin I measured in the coronary sinus at 
3 and 15 min and creatine kinase-MB 
at 15 min), indicating microdamage to 
cardiomyocytes. In both of these stud-
ies, the acoustic power and duration of 
imaging were far beyond what would 
occur in a typical clinical scenario. 
Furthermore, these studies have gener-
ally been carried out in subjects with 
normal underlying circulation, and thus 
the effects in the setting of ischemia 
or significant left ventricular dysfunc-
tion remain to be defined. In addition, 
contrast agents can increase pulmo-
nary artery pressure that might have 
accounted for the fatality in the patient 
with respiratory failure. Even without 
a specific mechanism, the fatal adverse 
events in unstable patients suggest that 
increased caution is appropriate.
What then will be the effect of the 
new product warning on clinical practice? 
First, it is important to remember that 
the actual risk associated with contrast is 
very small. These 4 deaths occurred on 
a background of approximately 2 mil-
lion injections. Three deaths (patients 
with advanced coronary disease) have 
also been reported with another agent 
(SonoVue, Bracco, Italy) but none with 
Optison. Serious side effects occur more 
frequently (with the exact rate unclear 
for Definity but reported at 0.014% for 
SonoVue and ≤0.002% for Optison) (7). 
Second, whereas the current focus is 
on specific commercial products (such 
as Optison and Definity), many more 
contrast echo studies use simple agitated 
saline to detect right to left shunts in 
patients with stroke, transient ischemic 
attacks, hypoxia, or suspected pulmo-
nary arteriovenous malformation. In our 
laboratory, for example, roughly 15% 
of all studies involve contrast; however, 
more than 80% of these studies use agi-
tated saline contrast. Although we have 
been using this agent for more than 
30 years and have never had a cardiac 
or other serious permanent complica-
tion, saline contrast will, on occasion, 
trigger a migraine headache, produce 
dizziness, or—rarely—cause a transient 
neurologic deficit. Thus, caution should 
be employed with all contrast injections, 
and it should be clear before doing the 
study that the result, if positive, would 
motivate some change in the therapeutic 
response. Finally, the new list of contra-
indications for Definity (and presumably 
all encapsulated microbubble contrast 
Even without a specific mechanism the fatal adverse events in unstable patients 
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agents), including worsening or unstable 
heart failure, acute coronary syndrome, 
serious ventricular arrhythmias, respi-
ratory failure, and severe pulmonary 
disease, and would preclude most appli-
cations in the intensive care unit/critical 
care unit. Likewise the recommendation 
that patients be monitored for 0.5 h 
after injection will limit use in portable 
studies on nonmonitored hospitalized 
patients and, in many laboratories will 
complicate outpatient studies. The use 
of contrast during stress studies would 
be easier, because patients are monitored 
during the study; this would only require 
extension of the post-procedure moni-
toring. These new warnings also raise 
the issue of informed consent. If this is 
deemed necessary it will further compli-
cate many studies, because the need for 
contrast enhancement is only obvious 
after initial images are obtained, and it 
would then be necessary to find a physi-
cian to obtain the consent, again delay-
ing the process. In the end, these new 
warnings do not preclude the use of con-
trast, particularly in situations where the 
information is important and is either 
not available in any other way or could 
only be obtained with tests that have 
their own inherent complications. They 
do, however, raise the level of awareness 
of potential complications and will likely 
further limit or delay the use of contrast 
in echocardiographic studies.
Action or Over-Reaction?
Jonathan R. Lindner, MD FACC 
and Kevin Wei, MD FACC
Oregon Health and Sciences University
A L T H O U G H  “ P R I M U M  N O N 
N O C E R E ” or “First, do no harm” is a 
basic tenet of the practice of medicine 
and reminds clinicians to do all to avoid 
unnecessary risks to patients, there are 
few drugs or medical procedures that 
are without risk. Even routine nonin-
vasive diagnostic tests used in the daily 
practice of cardiovascular medicine or 
the contrast agents employed during 
cardiac imaging are associated with 
risk for major adverse effects (Table 1) 
(8–12). Still these tests are frequently 
performed, because in an individual 
patient, the potential benefit of the 
information they provide outweighs the 
risk of not knowing.
What ratio of risk-to-benefit for a 
diagnostic test is favorable enough to 
be considered acceptable by the medi-
cal community and society in general? 
Although difficult to answer, this ques-
tion is important for the future of 
ultrasound contrast agents approved 
for use by the U.S. FDA (Definity 
and Optison). It was recently reported 
that the FDA had issued a “black box 
warning” for the use of 1 of these 
agents. Yet, insufficient information 
was provided by the agency to allow 
us, the clinicians who rely on the use 
of microbubble agents, to make reason-
able decisions regarding their relative 
risk in the circumstances in which they 
might be used. Information has now 
been made available upon request from 
the manufacturer of Definity for us to 
judge (4).
Post-marketing surveillance after 
approximately 2 million administered 
doses of Definity indicates that the 
risk for serious adverse cardiopulmonary 
effects is approximately 1 in 10,000 
cases. Most of these events are probably 
from non-immunoglobulin E–mediated 
or anaphylactoid reactions from local 
complement activation (13). It must 
be noted that this risk (0.01%) pales 
 in comparison to approved liposomal 
drug formulations such as Doxil and 
amphotericin, which require higher lipid 
doses and are associated with up to 7% 
risk. (14,15). It is also much lower than 
the 1 in 500 risk for anaphylactoid reac-
tion with ionic radiographic contrast 
agents (10).
Post-marketing surveys also detected 
4 cardiopulmonary deaths (risk approx-
imately 1 in 500,000) within 30 min 
of Definity administration. In 2 cases, 
the report claimed that death was likely 
unrelated to contrast administration. 
Both involved critically ill patients with 
heart failure who were in the intensive 
care unit, owing to decompensated 
condition. One of the 2 patients was 
on mechanical ventilation for bilateral 
pneumonia, was on multiple pressors, 
and had a large right ventricular throm-
bus. Autopsy demonstrated multiple 
pulmonary emboli. A third patient who 
also had severe ischemic heart failure 
and multiple comorbidities was also 
thought to have died from massive pul-
monary embolism. The sole outpatient 
case was in a patient with ischemic 
cardiomyopathy, diabetes, and heart 
failure. Thirty minutes after contrast 
administration, an exercise stress pro-
tocol was initiated without contrast, 
and the patient suffered an arrhythmic 
arrest soon thereafter.
What lessons do we learn from 
this vital information? First and fore-
most, there was no causation estab-
lished between injection of Definity 
and death. However, the FDA consid-
ers the 30-min interval to be impor-
tant in separating potential causation 
from other reasons. In most of the 4 
reported deaths there were alternative 
and much more likely explanations for 
cause of death according to the treating 
physician and/or post-mortem exami-
nation. Second, the risk of adverse 
cardiopulmonary effects reported with 
Definity is much lower than that for 
tests we routinely use in cardiology and 
deem to have an acceptable risk profile. 
For example, the various risk profiles 
depicted in Table 1 indicate that the 
outpatient death described in the pre-
vious paragraph was far more likely to 
be attributable to exercise stress rather 
than a contrast reaction.
So why are we permitted to continue 
exercise or dobutamine stress testing? 
This action against ultrasound contrast agents is not based on science and appears to be 
a result of political expediency by an agency that is keen to demonstrate it’s willingness 
to get ‘tough’ with pharmaceutical companies. 
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Why is there no outcry against the 
astounding growth of cardiac com-
puted tomography when, according to 
the data from the American College 
of Radiology (16),  the risk for seri-
ous, potentially life-threatening reac-
tion with the high-osmolar contrast 
agents is 10 times higher than that for 
Definity? In all likelihood, the seem-
ingly capricious action of the FDA 
against low-risk ultrasound contrast 
agents was the reaction of an agency 
that is “once bitten, twice shy.” Recent 
high-profile post-marketing problems 
with drugs such as Vioxx (Whitehouse 
Station, New Jersey) and Avandia 
(GSK, Morrisville, North Carolina) 
have altered the FDA’s tolerance for 
real or perceived risk. Ultrasound con-
trast agents are relatively new and not 
entrenched in clinical practice and thus 
vulnerable to FDA action. This action 
against ultrasound contrast agents is 
not based on science and seems to be 
a result of political expediency by an 
agency that is keen to demonstrate its 
willingness to get “tough” with phar-
maceutical companies.
Let us return to the idea of risk versus 
benefit, with the focus on the latter. It 
is now indisputable that contrast agents 
have made a very positive impact on 
clinical care. However, these agents are 
now contraindicated in patients who 
benefit the most from having accurate 
assessment of regional ventricular func-
tion, such as those with worsening 
heart failure. Another contraindica-
tion is suspected acute coronary syn-
drome, a situation where these agents 
have been shown to provide critical 
diagnostic and prognostic information, 
particularly when the electrocardio-
gram is nondiagnostic and the initial 
troponin is negative (17). Now, these 
patients might be exposed to either the 
higher risk associated with immediate 
diagnostic cardiac catheterization or a 
delay in diagnosis until further sero-
logic studies return.
In summary, the action by the FDA 
against ultrasound contrast agents has 
been based on post-marketing reports 
that, in reality, indicate a safety profile 
that is quite favorable compared with 
other alternative diagnostic tests. A 
balance must be reached by our regula-
tory agency. Warning and educating 
health care providers about previously 
unrecognized risks is an important and 
laudable goal. In this case, however, 
this stern and inappropriate overreac-
tion has eliminated our ability to make 
reasonable decisions regarding appro-
priate use of ultrasound contrast agents, 
even on a case-by-case basis.
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Table 1. Major Adverse Events Associated with Common Cardiovascular 
Diagnostic Tests or Contrast Agents
Procedure Adverse Event(s) Risk
Exercise stress testing (8) MI and death 1/2,500
Dobutamine stress testing (9) MI or ventricular fibrillation 1/2,000
Iodinated radiographic  Potentially or immediately life-threatening LOCM 2/1,000
contrast agents (10)  reactions (cardiopulmonary and neurologic) HOCM 2/10,000
Transesophageal echocardiography (11) Hypotension, cardiac arrest, pulmonary  1/2,000
 edema, laryngospasm  
Diagnostic cardiac catheterization (12) Death, MI, serious arrhythmia,  1/500
 neurologic event, vascular complication, 
 contrast reaction
HOCM = high-osmolarity contrast media; LOCM = low-osmolarity contrast media; MI = myocardial infarction.
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